Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Animal testing (2)
- Anti-TNF (2)
- Carcinogenicity (2)
- Laboratory animals (2)
- Medications (2)
-
- Pharmaceuticals (2)
- 3Rs (1)
- Acute toxicity (1)
- Antispasmodic (1)
- Biosimilar pharmaceuticals (1)
- Ca++ antagonist (1)
- DMARDs (biologic) (1)
- Economic Evaluations (1)
- Harmonization (1)
- Hazard labeling (1)
- Labiatae (1)
- Language Learning (1)
- Language immersion (1)
- Language pedagogy (1)
- Limit dose (1)
- Marrubiin (1)
- Outcomes research (1)
- Parallel-text (1)
- Pharmacokinetics (1)
- Phlomis bracteosa (1)
- Redundancy (1)
- Regulatory classification (1)
- Rheumatoid Arthritis (1)
- Systemic toxicity (1)
- Treatment (1)
Articles 1 - 7 of 7
Full-Text Articles in Chemicals and Drugs
The Changing Landscape Of Biosimilars In Rheumatology, Thomas Dorner, Vibeke Strand, Paul Cornes, Joao Goncalves, Laszlo Gulacsi, Jonathan Kay, Tore K. Kvien, Josef S. Smolen, Yoshiya Tanaka, Gerd R. Burmester
The Changing Landscape Of Biosimilars In Rheumatology, Thomas Dorner, Vibeke Strand, Paul Cornes, Joao Goncalves, Laszlo Gulacsi, Jonathan Kay, Tore K. Kvien, Josef S. Smolen, Yoshiya Tanaka, Gerd R. Burmester
Jonathan Kay
Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and health-economic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities …
Which Drugs Cause Cancer?, Andrew Knight, Jarrod Bailey, Jonathan Balcombe
Which Drugs Cause Cancer?, Andrew Knight, Jarrod Bailey, Jonathan Balcombe
Jarrod Bailey, PhD
Animal tests yield misleading results.
Biosimilars In Rheumatology: What The Clinician Should Know, Gilberto Castaneda-Hernandez, Rodrigo Gonzalez-Ramirez, Jonathan Kay, Morton A. Scheinberg
Biosimilars In Rheumatology: What The Clinician Should Know, Gilberto Castaneda-Hernandez, Rodrigo Gonzalez-Ramirez, Jonathan Kay, Morton A. Scheinberg
Jonathan Kay
Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars. The design of such trials, including equivalence and non-inferiority statistical approaches, are discussed. Clinical evidence on biosimilars that have been approved recently or are presently being developed for use in rheumatology is also reviewed and contrasted with that available for biomimics (or intended copies), which are non-innovator biologics that are marketed in several countries but have not undergone review according to a regulatory pathway for biosimilars.
Which Drugs Cause Cancer?, Andrew Knight, Jarrod Bailey, Jonathan Balcombe
Which Drugs Cause Cancer?, Andrew Knight, Jarrod Bailey, Jonathan Balcombe
Andrew Knight, Ph.D.
Animal tests yield misleading results.
Cross-Sector Review Of Drivers And Available 3rs Approaches For Acute Systemic Toxicity Testing, Troy Seidle, Sally Robinson, Tom Holmes, Stuart Creton, Pilar Prieto, Julia Scheel, Magda Chlebus
Cross-Sector Review Of Drivers And Available 3rs Approaches For Acute Systemic Toxicity Testing, Troy Seidle, Sally Robinson, Tom Holmes, Stuart Creton, Pilar Prieto, Julia Scheel, Magda Chlebus
Troy Seidle, PhD
Acute systemic toxicity studies are carried out in many sectors in which synthetic chemicals are manufactured or used and are among the most criticized of all toxicology tests on both scientific and ethical grounds. A review of the drivers for acute toxicity testing within the pharmaceutical industry led to a paradigm shift whereby in vivo acute toxicity data are no longer routinely required in advance of human clinical trials. Based on this experience, the following review was undertaken to identify (1) regulatory and scientific drivers for acute toxicity testing in other industrial sectors, (2) activities aimed at replacing, reducing, or …
Antispasmodic And Ca++ Antagonist Potential Of Marrubiin, A Labdane Type Diterpene From Phlomis Bracteosa, Javid Hussain, Riaz Ullah, Arif-Ullah Khan, Fazal Mabood, Mohammad Raza Shah, Ahmed Al-Harrasi, Anwar Gilani
Antispasmodic And Ca++ Antagonist Potential Of Marrubiin, A Labdane Type Diterpene From Phlomis Bracteosa, Javid Hussain, Riaz Ullah, Arif-Ullah Khan, Fazal Mabood, Mohammad Raza Shah, Ahmed Al-Harrasi, Anwar Gilani
Anwar Gilani
A tricyclic labdane type diterpene was isolated for the first time from ethyl acetate soluble part of Phlomis bracteosa. Its structure was confirmed by x-ray which was found to be marrubiin. When studied in isolated rabbit jejunum, marrubiin caused concentration-dependent relaxation of spontaneous and high K+ (80 mM)-induced contractions, like that caused by verapamil, indicating that marrubiin exhibits spasmolytic activity, possibly mediated through Ca++ channel blocking action.
Parallel Text Immersion, Daniel P. Becker Ph.D.
Parallel Text Immersion, Daniel P. Becker Ph.D.
Daniel P. Becker
A new method of teaching foreign languages to beginning, intermediate, and advancing foreign language students is proposed involving reading out loud passages, chapters, and entire works of literature that are familiar to the student through required pre-reading in the students’ mother tongue. Testing is proposed to evaluate the success of the method.